+

WO2008061995A3 - Ablation génétique du gène prp, cellules utilisant un piège à promoteur ciblé, stratégie pour la production de protéines recombinantes exemptes de sérum en tant que produits thérapeutiques - Google Patents

Ablation génétique du gène prp, cellules utilisant un piège à promoteur ciblé, stratégie pour la production de protéines recombinantes exemptes de sérum en tant que produits thérapeutiques Download PDF

Info

Publication number
WO2008061995A3
WO2008061995A3 PCT/EP2007/062597 EP2007062597W WO2008061995A3 WO 2008061995 A3 WO2008061995 A3 WO 2008061995A3 EP 2007062597 W EP2007062597 W EP 2007062597W WO 2008061995 A3 WO2008061995 A3 WO 2008061995A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
recombinant proteins
therapeuticals
serum
prp gene
Prior art date
Application number
PCT/EP2007/062597
Other languages
English (en)
Other versions
WO2008061995A2 (fr
Inventor
Carola Schroeder
Elisabeth Casademunt
Kim Bjoernstrup
Original Assignee
Octagene Gmbh
Carola Schroeder
Elisabeth Casademunt
Kim Bjoernstrup
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octagene Gmbh, Carola Schroeder, Elisabeth Casademunt, Kim Bjoernstrup filed Critical Octagene Gmbh
Priority to AU2007324530A priority Critical patent/AU2007324530A1/en
Priority to BRPI0718989-3A2A priority patent/BRPI0718989A2/pt
Priority to MX2009005277A priority patent/MX2009005277A/es
Priority to KR1020097012589A priority patent/KR20090106474A/ko
Priority to EP07847234A priority patent/EP2084269A2/fr
Priority to CA002670003A priority patent/CA2670003A1/fr
Publication of WO2008061995A2 publication Critical patent/WO2008061995A2/fr
Publication of WO2008061995A3 publication Critical patent/WO2008061995A3/fr
Priority to NO20091875A priority patent/NO20091875L/no
Priority to IL198770A priority patent/IL198770A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne une lignée cellulaire humaine somatique immortalisée exempte de protéine de prion (PrP), les deux allèles du gène PrP ayant été complètement délétés par recombinaison homologue. L'invention concerne en outre un procédé pour la production de ladite lignée cellulaire et son utilisation pour produire des protéines recombinantes humaines qui sont appropriées en tant que produits biopharmaceutiques.
PCT/EP2007/062597 2006-11-20 2007-11-20 Ablation génétique du gène prp, cellules utilisant un piège à promoteur ciblé, stratégie pour la production de protéines recombinantes exemptes de sérum en tant que produits thérapeutiques WO2008061995A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2007324530A AU2007324530A1 (en) 2006-11-20 2007-11-20 Genetic ablation of the PrP gene cells using a targeted promoter trap strategy for production of serum-free recombinant proteins as therapeuticals
BRPI0718989-3A2A BRPI0718989A2 (pt) 2006-11-20 2007-11-20 Ablação genética de células com gene prp usando uma estratégia de captura de promotor direcionada para a produção de proteínas recombinantes isentas de soro como produtos terapêuticos.
MX2009005277A MX2009005277A (es) 2006-11-20 2007-11-20 Ablacion genetica de celulas del gen prp utilizando una estrategia de trampa promotora dirigida para la produccion de proteinas recombinates sin suero como terapeuticos.
KR1020097012589A KR20090106474A (ko) 2006-11-20 2007-11-20 혈청-불포함 재조합 단백질의 치료제로서의 제조를 위한 표적화된 프로모터 트랩 전략을 이용한 ｐｒｐ 유전자 세포의 유전적 제거
EP07847234A EP2084269A2 (fr) 2006-11-20 2007-11-20 Ablation génétique du gène prp, cellules utilisant un piège à promoteur ciblé, stratégie pour la production de protéines recombinantes exemptes de sérum en tant que produits thérapeutiques
CA002670003A CA2670003A1 (fr) 2006-11-20 2007-11-20 Ablation genetique du gene prp, cellules utilisant un piege a promoteur cible, strategie pour la production de proteines recombinantes exemptes de serum en tant que produits therapeutiques
NO20091875A NO20091875L (no) 2006-11-20 2009-05-13 Genetisk ablasjon av PRP genceller ved anvendelse av en malsokt strategi for produksjon av serum
IL198770A IL198770A0 (en) 2006-11-20 2009-05-14 Genetic ablation of the prp gene cells using a targeted promoter trap strategy for production of serum-free recombinant proteins as therapeuticals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124427 2006-11-20
EP06124427.3 2006-11-20

Publications (2)

Publication Number Publication Date
WO2008061995A2 WO2008061995A2 (fr) 2008-05-29
WO2008061995A3 true WO2008061995A3 (fr) 2008-07-10

Family

ID=37685785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/062597 WO2008061995A2 (fr) 2006-11-20 2007-11-20 Ablation génétique du gène prp, cellules utilisant un piège à promoteur ciblé, stratégie pour la production de protéines recombinantes exemptes de sérum en tant que produits thérapeutiques

Country Status (12)

Country Link
EP (1) EP2084269A2 (fr)
KR (1) KR20090106474A (fr)
CN (1) CN101605891A (fr)
AU (1) AU2007324530A1 (fr)
BR (1) BRPI0718989A2 (fr)
CA (1) CA2670003A1 (fr)
IL (1) IL198770A0 (fr)
MX (1) MX2009005277A (fr)
NO (1) NO20091875L (fr)
RU (1) RU2009123458A (fr)
WO (1) WO2008061995A2 (fr)
ZA (1) ZA200903429B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011250912A1 (en) * 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010227A1 (fr) * 1991-11-14 1993-05-27 Charles Weissmann Animaux transgeniques exempts de prions
US5627059A (en) * 1989-08-22 1997-05-06 University Of Utah Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
WO2000037612A1 (fr) * 1998-12-22 2000-06-29 The Regents Of The University Of California Cellules somatiques avec gene prp retire et leurs methodes d'utilisation
WO2001073107A1 (fr) * 2000-03-24 2001-10-04 University Of Massachusetts, A Public Institution Of The Commonwealt Of Massachusettes, As Represented By Its Amherst Campus Ongules transgeniques depourvus de prion
WO2002074935A2 (fr) * 2001-03-21 2002-09-26 Geron Corporation Utilisation de la transcriptase inverse de la telomerase dans la creation d'animaux knockout homozygotes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627059A (en) * 1989-08-22 1997-05-06 University Of Utah Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
WO1993010227A1 (fr) * 1991-11-14 1993-05-27 Charles Weissmann Animaux transgeniques exempts de prions
WO2000037612A1 (fr) * 1998-12-22 2000-06-29 The Regents Of The University Of California Cellules somatiques avec gene prp retire et leurs methodes d'utilisation
WO2001073107A1 (fr) * 2000-03-24 2001-10-04 University Of Massachusetts, A Public Institution Of The Commonwealt Of Massachusettes, As Represented By Its Amherst Campus Ongules transgeniques depourvus de prion
WO2002074935A2 (fr) * 2001-03-21 2002-09-26 Geron Corporation Utilisation de la transcriptase inverse de la telomerase dans la creation d'animaux knockout homozygotes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HANSON KEITH D ET AL: "Analysis of biological selections for high-efficiency gene targeting", MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 1, 1995, pages 45 - 51, XP002418917, ISSN: 0270-7306 *
SEDIVY J M ET AL: "GENE TARGETING AND SOMATIC CELL GENETICS A REBIRTH OR A COMING OF AGE?", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 15, no. 3, March 1999 (1999-03-01), pages 88 - 90, XP001153933, ISSN: 0168-9525 *

Also Published As

Publication number Publication date
EP2084269A2 (fr) 2009-08-05
RU2009123458A (ru) 2010-12-27
CA2670003A1 (fr) 2008-05-29
KR20090106474A (ko) 2009-10-09
WO2008061995A2 (fr) 2008-05-29
CN101605891A (zh) 2009-12-16
AU2007324530A1 (en) 2008-05-29
ZA200903429B (en) 2010-04-28
MX2009005277A (es) 2009-05-28
NO20091875L (no) 2009-07-28
BRPI0718989A2 (pt) 2014-02-11
IL198770A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
Li et al. Active DNA demethylation: mechanism and role in plant development
CY1121516T1 (el) ΣΤΕΡΟΕΙΔΕΣ ΠΑΡΑΓΩΓΟ ΓΙΑ ΠΑΡΟΧΗ mRNA ΣΕ ΠΕΡΙΠΤΩΣΕΙΣ ΑΝΘΡΩΠΙΝΩΝ ΓΕΝΕΤΙΚΩΝ ΝΟΣΩΝ
WO2012075040A3 (fr) Arnm pour l'utilisation dans le traitement de maladies génétiques humaines
WO2007014275A3 (fr) Integration et expression ciblees de sequences d'acides nucleiques exogenes
WO2010051049A3 (fr) Gènes et enzymes de glycosylation thermophiles et thermoacidophiles provenant d'alicyclobacillus acidocaldarius et d'organismes apparentés, et procédés
JP2021045158A (ja) Ｐｐｒモチーフを利用したｄｎａ結合性タンパク質およびその利用
WO2012145624A3 (fr) Compositions à base de raav et procédés pour traiter des déficiences en anti-trypsine alpha-1
WO2008091908A3 (fr) Cellules souches cancéreuses humaines
EP4219522A3 (fr) Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
MX2007003906A (es) Metodos y composiciones para mejorar la produccion de proteinas recombinantes.
WO2006073727A3 (fr) Constructions d'adn recombinant et procedes pour le controle de l'expression genetique
MX336807B (es) Composiciones y metodos para producir una composicion.
WO2008070082A3 (fr) Acides microribonucléiques spécifiques de cellule souche de progéniteur et leurs utilisations
IN2012DN03368A (fr)
WO2011091350A3 (fr) Procédés et compositions pour améliorer la production de protéines
WO2009086215A3 (fr) Analyse de voies de phénotypes de culture de cellules et utilisations de celle-ci
WO2006079045A3 (fr) Evaluation transgenique d'alleles mutants actives de sos2 revelant un besoin critique d'activite de kinase et domaine regulatoire c-terminal pour tolerance au sel chez arabidopsis thaliana
EP2935319A2 (fr) Production de protéines thérapeutiques dans des cellules de mammifère génétiquement modifiées
WO2008054514A3 (fr) Analyse différentielle de profils d'expression de phénotypes de cultures de cellules et utilisations de celle-ci
WO2006044492A3 (fr) Methodes de generation de lignees cellulaires derivees d'embryons de rats et de modification genetique de genome de rats
WO2007044627A3 (fr) Compositions et methodes d'administration d'arn interferant
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
WO2008061995A3 (fr) Ablation génétique du gène prp, cellules utilisant un piège à promoteur ciblé, stratégie pour la production de protéines recombinantes exemptes de sérum en tant que produits thérapeutiques
ES2688727T3 (es) Reducción de la formación de aminoácidos amidados en líneas celulares para la expresión de proteína
WO2005090393A3 (fr) Toxines proteiques multimeriques destinees a cibler des cellules possedant plusieurs caracteristiques d'identification

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780046653.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07847234

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007324530

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 198770

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/005277

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009536753

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2670003

Country of ref document: CA

Ref document number: 2007847234

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007324530

Country of ref document: AU

Date of ref document: 20071120

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097012589

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009123458

Country of ref document: RU

Kind code of ref document: A

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0718989

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090520

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载